Navigation Links
Anavex Appoints Alzheimer's Industry Leader to Scientific Advisory Board

NEW YORK, Dec. 3, 2013 /PRNewswire/ -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB: AVXL) today announced the appointment of Michael Gold, MD, as a member of its Scientific Advisory Board.  Dr. Gold has over 20 years of experience in the clinical development of Alzheimer's and other central nervous system (CNS) drugs and currently serves as Vice President of the CNS practice at UCB, Inc., a global biopharmaceutical company.  His background also includes leadership roles with GlaxoSmithKline (GSK), Johnson & Johnson (J&J) and Bristol-Myers Squibb (BMS).

At GSK, Dr. Gold was responsible for the late-stage CNS and pain portfolio.  He also led several clinical Phase II and Phase III Alzheimer's disease-related project teams.  At J&J, Dr. Gold served as the Compound Development Team Leader for Galantamine, an Alzheimer's drug, culminating in FDA approval of Galantamine CR (Razadyne® ER).  Prior to joining UCB, Dr. Gold served as the Chief Medical Officer of Allon Therapeutics, where he led a large pan-US and European clinical study for a neurodegenerative disease.

Before joining the pharmaceutical industry, Dr. Gold was an Assistant Professor at the University of South Florida (USF) College of Medicine Department of Neurology and Director of the USF Memory Disorders Clinic.  During this time, he was the Principal Investigator for several clinical trials for Alzheimer's disease.  He has also authored multiple publications related to Alzheimer's and dementia. Dr. Gold also holds an academic appointment as an adjunct assistant professor in the Department of Medicine at the University of North Carolina at Chapel Hill.

"We are excited to welcome Dr. Gold as an advisor to the Company," said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex.  "Dr. Gold brings substantial experience and expertise which we expect will be invaluable to Anavex as we execute on our strategic and organic growth initiatives."

"I am proud to join Anavex and help advance the Company's promising drug pipeline," said Dr. Gold.  "I look forward to helping guide the development of Anavex's breakthrough treatments for Alzheimer's and other CNS indications."

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. ( is a clinical stage biopharmaceutical company engaged in the development of novel drug candidates to treat Alzheimer's, CNS diseases and various types of cancer. ANAVEX 2-73, an orally available drug candidate developed to treat Alzheimer's through potential disease modification, has undergone an initial Phase 1 human clinical trial and was well tolerated in doses up to 55mg. Results from pre-clinical studies indicate that ANAVEX 2-73 demonstrates anti-amnesic and neuroprotective properties.  A highly encouraging synergistic effect has also been observed between ANAVEX 2-73 and Aricept® (donepezil).  The combined therapeutics produced up to 80% greater reversal of memory loss in Alzheimer's disease models versus when the drugs were used individually. Anavex is a publicly traded corporation quoted as AVXL.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties.  Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company's most recent Annual Report on Form 10-K filed with the SEC.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.  All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For Further Information

Anavex Life Sciences Corp.
Research & Business Development

Shareholder & Media Relations

Toll-free: 1-866-505-2895
Outside North America: +1 (416) 489-0092


SOURCE Anavex Life Sciences Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Anavex Reports Predicted Clinical Effect for ANAVEX 2-73 in Computer Simulation Model of Alzheimers Disease
2. Anavex Announces Expansion of Scientific Advisory Board
3. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
4. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
5. Nephros Appoints John C. Houghton as President and Chief Executive Officer
6. Elsevier Appoints New President of Elsevier CPM Resource Center
7. GenWay Biotech Appoints New Vice President of Custom/OEM
8. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
9. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
10. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
11. Hill-Rom Appoints Alton Shader President of Hill-Rom North America
Post Your Comments:
(Date:10/13/2015)... SAN FRANCISCO , October 13, 2015 ... it will be sharing additional findings from the multicenter ... Therapeutics (TCT) meeting in San Francisco ... Device , announced that it will be sharing additional ... community at the Trans-Catheter Therapeutics (TCT) meeting in ...
(Date:10/13/2015)... , Oct. 13, 2015  The spine division of ... in musculoskeletal healthcare, will showcase its portfolio of innovative ... Society (NASS) annual meeting, October 14-17, 2015, in ... host two clinical events: "Supplemental MIS Fixation ... Wednesday, October 14 12:30 – 1 p.m. --> ...
(Date:10/13/2015)... , Oct. 13, 2015  Human Longevity, Inc. (HLI), ... of medicine, announced today the launch of the company,s ... that has the potential to transform healthcare. The inaugural ... CA , at HLI,s headquarters facility. More Health ... other US and International cities. ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 2015 , ... Sir Grout of Greater Boston donated an expansive, seven room ... McDonald House Charities® (RMHC®). This donation was made in an effort to give back ... its inception. , “We believe strongly in the Ronald McDonald House Charities, and they ...
(Date:10/13/2015)... Diego, CA (PRWEB) , ... October 13, 2015 ... ... launch of its newest technology platform, ENGAGE, at HIMSS’s Patient Engagement Summit ... to end. , ENGAGE delivers innovative health programs and interventions via mobile devices ...
(Date:10/13/2015)... ... 2015 , ... Element Blue ™, a leading IT ... RightSensor™ LLC, an Internet of Things (IoT) hardware supplier that delivers custom and ... for customers requiring sensor hardware for critical data environments. , RightSensor™, working with ...
(Date:10/13/2015)... ... October 13, 2015 , ... NavaFit Inc. today announced the launch of its ... with, participate in local fitness & sporting events, and stay motivated. Users ... medical costs drive us to get more serious about fitness and wellness, individuals are ...
(Date:10/13/2015)... (PRWEB) , ... October 13, ... ... Postnatal Omega-3, a first-of-its kind product that targets the unique health needs ... Omega-3” of the American Pregnancy Association ( ), utilizes Nordic Naturals’ ...
Breaking Medicine News(10 mins):